Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) Director Howard G. Welgus sold 8,500 shares of the business’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $13.97, for a total transaction of $118,745.00. Following the completion of the sale, the director now directly owns 165,825 shares in […]
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) had its price objective trimmed by Morgan Stanley from $50.00 to $47.00 in a research note released on Wednesday morning, The Fly reports. The brokerage currently has an overweight rating on the stock. ARQT has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an overweight […]
Mizuho reaffirmed their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) in a research note published on Tuesday morning, Benzinga reports. Mizuho currently has a $61.00 target price on the stock. Several other research firms have also recently commented on ARQT. Needham & Company LLC cut their target price on Arcutis Biotherapeutics […]
Mizuho reaffirmed their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) in a research note released on Tuesday morning, Benzinga reports. Mizuho currently has a $61.00 price target on the stock. ARQT has been the topic of several other reports. Truist Financial decreased their target price on shares of Arcutis Biotherapeutics from […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) Director Howard G. Welgus sold 8,500 shares of the company’s stock in a transaction on Thursday, April 6th. The stock was sold at an average price of $12.01, for a total value of $102,085.00. Following the completion of the sale, the director now owns 165,825 shares of the […]